Dimension and Bayer join forces to develop gene therapy for Hemophilia A
Dimension Therapeutics has entered into a collaboration with Bayer HealthCare for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. Dimension has been funded by Fidelity Biosciences and OrbiMed Advisors.
23 June 2014•3 mins read
